UB Paderborn / Katalog / Suche / in CDI

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

The lancet oncology, 2017-01, Vol.18 (1), p.42-51

2017

Link zum Volltext

Verfügbarkeit prüfen

Antibody–Drug Conjugates as Cancer Therapeutics: Past, Present, and Future

Journal of clinical pharmacology, 2017-10, Vol.57 (S10), p.S11-S25

2017

Link zum Volltext

Verfügbarkeit prüfen

Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager

PloS one, 2024-05, Vol.19 (5), p.e0300174

2024

Link zum Volltext

Verfügbarkeit prüfen

Dynamic Cell and Microparticle Control via Optoelectronic Tweezers

Journal of microelectromechanical systems, 2007-06, Vol.16 (3), p.491-499

2007

Link zum Volltext
IEEE_Xplore

Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates

Drug metabolism and disposition, 2014-11, Vol.42 (11), p.1914

2014

Link zum Volltext

Verfügbarkeit prüfen

Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects

Journal of clinical pharmacology, 2007-07, Vol.47 (7), p.834-840

2007

Link zum Volltext

Verfügbarkeit prüfen

Kinetic feasibility of nitroxyl reduction by physiological reductants and biological implications

Free radical biology & medicine, 2009-10, Vol.47 (8), p.1130-1139

2009

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies

Journal of clinical pharmacology, 2017-09, Vol.57 (9), p.1148-1158

2017

Link zum Volltext

Verfügbarkeit prüfen

Nitric Oxide is Consumed, Rather Than Conserved, by Reaction with Oxyhemoglobin under Physiological Conditions

Proceedings of the National Academy of Sciences - PNAS, 2002-08, Vol.99 (16), p.10341-10346

2002

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

Clinical cancer research, 2012, Vol.18 (1), p.248-255

2012

Link zum Volltext

Verfügbarkeit prüfen

Modulation of Nitric Oxide Bioavailability by Erythrocytes

Proceedings of the National Academy of Sciences - PNAS, 2001-09, Vol.98 (20), p.11771-11776

2001

Link zum Volltext

Verfügbarkeit prüfen

Nitric Oxide Reaction with Red Blood Cells and Hemoglobin under Heterogeneous Conditions

Proceedings of the National Academy of Sciences - PNAS, 2002-05, Vol.99 (11), p.7763-7768

2002

Link zum Volltext

Verfügbarkeit prüfen

Erythrocyte nitric oxide transport reduced by a submembrane cytoskeletal barrier

Biochimica et biophysica acta, 2005-05, Vol.1723 (1), p.135-142

2005

Link zum Volltext

Verfügbarkeit prüfen

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment

British journal of clinical pharmacology, 2016-09, Vol.82 (3), p.696-705

2016

Link zum Volltext

Verfügbarkeit prüfen

CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies

Journal of clinical pharmacology, 2013-08, Vol.53 (8), p.866-877

2013

Link zum Volltext

Verfügbarkeit prüfen

Nitric Oxide Metabolism in Adults With Cyanotic Congenital Heart Disease

The American journal of cardiology, 2007-03, Vol.99 (5), p.691-695

2007

Link zum Volltext

Verfügbarkeit prüfen

Antioxidant actions of nitroxyl (HNO)

Free radical biology & medicine, 2007-02, Vol.42 (4), p.482-491

2007

Link zum Volltext

Verfügbarkeit prüfen

CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption

European journal of drug metabolism and pharmacokinetics, 2018-06, Vol.43 (3), p.347-354

2018

Link zum Volltext

Verfügbarkeit prüfen

Characterizing the PK/PD relationship for inhibition of capsaicin‐induced dermal vasodilatation by MK‐3207, an oral calcitonin gene related peptide receptor antagonist

British journal of clinical pharmacology, 2015-05, Vol.79 (5), p.831-837

2015

Link zum Volltext

Verfügbarkeit prüfen

Single- and Multiple-Dose Pharmacokinetics and Tolerability of Telcagepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, in Adults

Journal of clinical pharmacology, 2010-12, Vol.50 (12), p.1367-1376

2010

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Tolerability of Rizatriptan in Pediatric Migraineurs in a Randomized Study

Headache, 2012-04, Vol.52 (4), p.625-635

2012

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases

Asia-Pacific journal of clinical oncology, 2010-03, Vol.6 (1), p.42-48

2010

Link zum Volltext

Verfügbarkeit prüfen

Lack of Effect of Aprepitant or Its Prodrug Fosaprepitant on QTc Intervals in Healthy Subjects

Anesthesia and analgesia, 2009-08, Vol.109 (2), p.418-425

2009

Link zum Volltext

Verfügbarkeit prüfen

Power grid aware timing analysis using S-parameter

International journal of electronics, 2010-07, Vol.97 (7), p.759-772

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5548: The therapeutic potential of AMV564, a novel bispecific bivalent (2x2) T-cell engager, for the treatment of CD33-expressing hematologic malignancies

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5548-5548

2018

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Antibody–Drug Conjugates as Cancer Therapeutics: Past, Present, and Future

Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager

Dynamic Cell and Microparticle Control via Optoelectronic Tweezers

Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates

Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects

Kinetic feasibility of nitroxyl reduction by physiological reductants and biological implications

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies

Nitric Oxide is Consumed, Rather Than Conserved, by Reaction with Oxyhemoglobin under Physiological Conditions

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

Modulation of Nitric Oxide Bioavailability by Erythrocytes

Nitric Oxide Reaction with Red Blood Cells and Hemoglobin under Heterogeneous Conditions

Erythrocyte nitric oxide transport reduced by a submembrane cytoskeletal barrier

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment

CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies

Nitric Oxide Metabolism in Adults With Cyanotic Congenital Heart Disease

Antioxidant actions of nitroxyl (HNO)

CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption

Characterizing the PK/PD relationship for inhibition of capsaicin‐induced dermal vasodilatation by MK‐3207, an oral calcitonin gene related peptide receptor antagonist

Single- and Multiple-Dose Pharmacokinetics and Tolerability of Telcagepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, in Adults

Pharmacokinetics and Tolerability of Rizatriptan in Pediatric Migraineurs in a Randomized Study

Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases

Lack of Effect of Aprepitant or Its Prodrug Fosaprepitant on QTc Intervals in Healthy Subjects

Power grid aware timing analysis using S-parameter

Abstract 5548: The therapeutic potential of AMV564, a novel bispecific bivalent (2x2) T-cell engager, for the treatment of CD33-expressing hematologic malignancies

Suchergebnisse filtern